Moreover, RPL15 knockdown in B16-F10 murine melanoma cells sensitized B16-F10 tumors to anti-PD-1 antibody treatment, suggesting that targeting RPL15 may improve ICI efficacy. Here, RPL15 is linked to melanoma.